Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

作者：Yelena Y. Janjigian, Akihito Kawazoe, Yuxian Bai, Jianming Xu, Sara Lonardi, Jean Phillipe Metges, Patricio Yañez, Lucjan Wyrwicz, Lin Shen, Yuriy Ostapenko, Mehmet Bilici, Hyun Cheol Chung, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Kan Li, Chie‐Schin Shih, Pooja Bhagia, Sun Young Rha · 发表于：The Lancet · 年份：2023 · DOI：10.1016/s0140-6736(23)02033-0 · 被引用次数：514 · 研究领域：HER2/EGFR in Cancer Research、Gastric Cancer Management and Outcomes、Cancer Immunotherapy and Biomarkers